SCHEMBL3015429

SCHEMBL3015429

CCc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4c(F)cccc4F)CC3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.41
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PKM P14618 2/20 0.36
PKLR P30613 2/20 0.36
MAPK1 P28482 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
APLNR P35414 1/20 0.34
DNM1L O00429 2/20 0.34
HRH3 Q9Y5N1 1/20 0.34
CXCR2 P25025 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
OGA O60502 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003782 0.92 AR (0.40) ARNPC1RAB9ASMN1; SMN2PKM
SCHEMBL3016154 0.92 AR (0.41) ARNPC1RAB9ASMN1; SMN2PKM
SCHEMBL3013308 0.91 NPC1 (0.42) ARNPC1RAB9ASMN1; SMN2PKM
SCHEMBL3001952 0.90 AR (0.39) ARNPC1RAB9ASMN1; SMN2PKM
SCHEMBL3013007 0.90 HRH3 (0.35) ARNPC1RAB9ASMN1; SMN2MAPK1
SCHEMBL3013107 0.90 AR (0.38) ARNPC1RAB9ASMN1; SMN2PKM
SCHEMBL3009607 0.90 MAPT (0.41) ARNPC1RAB9ASMN1; SMN2PKM
SCHEMBL3022973 0.88 AR (0.39) ARNPC1RAB9ASMN1; SMN2PKM
SCHEMBL3010508 0.88 AR (0.39) ARNPC1RAB9ASMN1; SMN2PKM
SCHEMBL3012860 0.87 AR (0.41) ARNPC1RAB9ASMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885NPC1 15/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.